Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most claims (brand/active ingredient, oral tablet strength, MOA, indication, and general dosing-phase pattern) are consistent with the provided label excerpts. Minor issues include an imprecise statement about what the “120 mg” represents and an unsupported generalization about “many regimens” and phase correspondence without explicit label support.
Category Scores
Accurate Statements
Orgovyx is the brand name for relugolix.
Drug and active ingredient provided in prompt: ORGOVYX (relugolix).
Relugolix is an oral androgen receptor pathway inhibitor.
The label mechanism provided states relugolix is a nonpeptide GnRH receptor antagonist; it is not described as an androgen receptor pathway inhibitor. (This statement is therefore not label-supported as written; see unsupported section.)
Relugolix is used to treat advanced prostate cancer.
INDICATIONS AND USAGE: ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer.
Relugolix is used for patients for whom androgen suppression is appropriate.
DOSAGE AND ADMINISTRATION excerpt: In patients treated with GnRH receptor agonists and antagonists for prostate cancer, treatment is continued upon development of castration-resistant disease. (Label excerpts do not explicitly use the phrase “androgen suppression is appropriate,” but the indication and MOA support androgen deprivation context.)
Dosing depends on the treatment phase prescribed by the clinician.
DOSAGE AND ADMINISTRATION: initiate with 360 mg loading dose on Day 1 then 120 mg once daily; also restart with loading dose if interrupted >7 days. (Label does not mention clinician-prescribed “phases,” but dose does change by regimen timing/conditions.)
Many relugolix regimens use an initial higher dose and then a lower maintenance dose.
DOSAGE AND ADMINISTRATION: loading dose of 360 mg on first day followed by 120 mg once daily.
120 mg corresponds to one of the treatment phases in many relugolix regimens.
DOSAGE AND ADMINISTRATION: continue treatment with a 120 mg dose taken orally once daily after the 360 mg loading dose.
Unsupported Statements
"120 mg" refers to the strength of the tablets.
The label excerpt confirms tablets are 120 mg (section 3 DOSAGE FORMS AND STRENGTHS), but the claim specifically ties “120 mg” to tablet strength; while likely consistent, the provided label excerpt does not explicitly state that “120 mg” (as a label term) refers to tablet strength in the same sentence. This is treated as only weakly supported by the provided sections.
Relugolix is an oral androgen receptor pathway inhibitor.
The provided label mechanism of action describes relugolix as a nonpeptide GnRH receptor antagonist, not an androgen receptor pathway inhibitor.
Many relugolix regimens use an initial higher dose and then a lower maintenance dose.
The label excerpt provides the recommended regimen (loading then daily dosing), but does not explicitly support the generalization “many relugolix regimens.”
Contradictions
Low
AI Statement
Relugolix is an oral androgen receptor pathway inhibitor.
Label Reference
12.1 Mechanism of Action: “Relugolix is a nonpeptide GnRH receptor antagonist…”
Important Omissions
Boxed warnings, detailed warnings/precautions content (e.g., QT/QTc prolongation, hypersensitivity, embryo-fetal toxicity) and drug interaction specifics are not addressed by the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most claims are about identity, indication, and general dosing pattern. However, the MOA description is incorrect (“androgen receptor pathway inhibitor” vs GnRH receptor antagonist). Incorrect mechanism and generalized dosing-phase statements could mislead interpretation of treatment rationale, though the dosing pattern claims align with the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Mechanism of action claim is contradicted by the label (GnRH receptor antagonist vs androgen receptor pathway inhibitor). Generalizations about “many regimens” are not explicitly supported.
Suggested Improvement
Replace the MOA wording with the label’s description (nonpeptide GnRH receptor antagonist). Avoid or qualify generalized phrasing like “many regimens”; instead describe the specific labeled regimen (360 mg loading dose on Day 1 then 120 mg once daily).